36 results on '"Rossini, Bernardo"'
Search Results
2. Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology
3. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials
4. Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
5. Supplementary Table Legend from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
6. Supplementary Table from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
7. Supplementary Figure 5 from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
8. Supplementary Figure 1 from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
9. Supplementary Figure Legends from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
10. Supplementary Figure 2 from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
11. Supplementary Methods from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
12. Supplementary Figure 3 from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
13. Supplementary Figure 6 from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
14. Supplementary Figure 4 from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
15. Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs
16. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma
17. Primary, Bilateral and Diffuse Renal Non-Hodgkin’s Lymphoma in a Young Woman Suffering from Turner Syndrome
18. P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies
19. ARGO, Automatic Record Generator for Oncology: a natural language process-based tool to capture pathology features from onco-hematological reports (Preprint)
20. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients
21. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure
22. EARLY ANAEMIA CORRECTION WITH EPO: ONE YEAR EFFECTS ON LVH AND PROGRESSION OF CHRONIC RENAL FAILURE (CRF) IN PREDIALYSIS PATIENTS (PTS)
23. Is whole body low dose CT still necessary in the era of 18FFDG PET/CT for the assessment of bone disease in multiple myeloma patients?
24. Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?
25. Pentraxin 3(PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients
26. Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma
27. Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences
28. Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
29. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross‐talk in the bone marrow of multiple myeloma patients
30. One Year of Clinical Experience in Postdilution Hemofiltration with Online Reinfusion of Regenerated Ultrafiltrate
31. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.
32. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
33. Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences.
34. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
35. Is whole body low dose CT still necessary in the era of 18 F-FDG PET/CT for the assessment of bone disease in multiple myeloma patients?
36. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.